summar
find
sarscov
infect
sever
anim
model
support
viral
replic
lung
accompani
histopatholog
chang
andor
clinic
sign
ill
vari
degre
new
find
report
sarscov
replic
associ
patholog
two
addit
strain
age
mice
also
provid
new
compar
data
viral
replic
associ
patholog
follow
infect
golden
syrian
hamster
variou
sarscov
strain
report
level
neutral
antibodi
titer
follow
infect
crossprotect
efficaci
infect
strain
protect
heterolog
challeng
final
summar
find
varieti
vaccin
approach
discuss
avail
vitro
vivo
data
address
potenti
diseas
enhanc
follow
reinfect
anim
previous
vaccin
infect
sarscov
studi
pathogenesi
prophylaxi
treatment
anim
model
mimic
human
diseas
protect
diseas
invalu
sinc
outbreak
sever
acut
respiratori
syndrom
sar
late
identif
etiolog
agent
novel
coronaviru
sarscov
sever
anim
model
identifi
use
evalu
although
model
review
articl
util
studi
sar
diseas
prevent
kinet
viral
replic
resolut
diseas
much
rapid
anim
model
compar
human
infect
model
fulli
reflect
spectrum
clinic
ill
morbid
mortal
associ
patholog
viral
replic
observ
human
case
sar
anim
model
employ
evalu
sarscov
replic
diseas
model
fulli
character
offer
best
potenti
evalu
prevent
therapeut
strategi
discuss
includ
inbr
mice
hamster
ferret
nonhuman
primat
also
refer
less
wellcharacter
anim
model
number
approach
develop
sar
vaccin
explor
includ
inactiv
wholeviru
protein
subunit
live
virusvector
dnavector
combin
vaccin
review
data
avail
evalu
candid
vaccin
lastli
address
potenti
enhanc
diseas
follow
exposur
sarscov
previous
vaccin
anim
potenti
phenomenon
given
special
consider
immun
kitten
coronaviru
vaccin
felin
infecti
periton
viru
fipv
led
exacerb
diseas
follow
challeng
fipv
led
concern
specul
potenti
diseas
enhanc
follow
use
sar
vaccin
sever
inbr
mous
speci
balbc
shown
support
sarscov
replic
demonstr
pneumon
clinic
sign
sar
diseas
age
balbc
glass
et
al
hogan
et
al
robert
et
al
subbarao
et
al
inbr
mous
model
sever
advantag
includ
small
size
cost
avail
larg
enough
number
statist
evalu
abil
manipul
genet
level
ie
develop
gene
knockout
knockin
addit
immunolog
reagent
avail
studi
element
pathogenesi
mani
inbr
mous
strain
follow
intranas
inocul
light
anesthesia
sarscov
replic
epithelium
nasal
turbin
lung
mice
earli
one
day
postinfect
pi
peak
titer
lung
occur
day
pi
viru
clear
mice
day
piin
young
mice
sarscov
replic
associ
overt
sign
clinic
ill
pronounc
patholog
howev
mice
seem
slightli
suscept
diseas
associ
sarscov
infect
balbc
mice
evidenc
approxim
loss
bodi
weight
nadir
day
pi
presenc
mild
interstiti
pneumon
day
pi
hogan
et
al
author
unpublish
data
interstiti
pneumon
follow
sarscov
infect
previous
report
balbc
mice
evalu
day
pi
howev
slightli
elev
level
proinflammatori
cytokin
tnfalpha
observ
young
balbc
mice
day
pi
author
unpublish
data
upon
recent
evalu
young
balbc
mice
display
moder
interstiti
pneumon
day
pi
compar
seen
mice
glass
et
al
author
unpublish
data
pneumon
quickli
resolv
observ
day
pi
transient
inflamm
coincid
viral
clearanc
sinc
littl
viral
antigen
observ
day
pi
viru
titer
lung
also
steadili
declin
day
pi
onward
age
balbc
mice
develop
sever
diseas
young
balbc
mice
pattern
agerel
sever
mimic
observ
sar
outbreak
human
age
predictor
sever
diseas
mortal
addit
serv
model
agerel
suscept
diseas
age
balbc
mice
consist
demonstr
sever
featur
ideal
anim
model
sarscov
studi
addit
support
viral
replic
respiratori
tissu
age
balbc
mous
balbcannhsd
harlan
demonstr
clinic
sign
ill
includ
weight
loss
dehydr
ruffl
fur
sever
histopatholog
find
ie
diffus
alveolar
damag
includ
edema
hyalin
membran
format
pneumon
correl
report
autopsi
sar
patient
also
examin
suscept
age
jackson
laboratori
tacon
mice
sarscov
infect
follow
intranas
inocul
tcid
sarscov
urbani
age
mice
month
old
weight
loss
nadir
day
day
pi
compar
observ
age
balbc
mice
level
kinet
viral
replic
lung
age
balbc
mice
follow
inocul
also
similar
day
pi
sarscovinfect
mice
fold
lower
titer
viru
balbc
mice
figur
contrast
age
mice
support
prolong
replic
sarscov
viru
clear
lung
day
pi
data
shown
nevertheless
earli
histopatholog
featur
lung
age
mice
similar
seen
age
balbc
mice
follow
sarscov
infect
chang
observ
lung
day
pi
includ
perivascular
peribronchiolar
mononuclear
inflammatori
infiltr
intralumin
necrot
debri
bronchiol
compris
dead
respiratori
epithelium
inflammatori
cell
small
foci
interstiti
pneumon
figur
c
e
viral
antigen
detect
immunohistochem
ihc
stain
respiratori
epitheli
cell
bronchiol
alveolar
pneumocyt
mous
strain
day
pi
appear
abund
bronchiol
mice
time
point
figur
b
c
f
vari
amount
mononuclear
inflammatori
infiltr
persist
around
bronchiol
small
pulmonari
vessel
day
pi
howev
viral
antigen
detect
ihc
time
point
previous
report
age
balbc
mous
featur
would
make
excel
model
evalu
pathogenesi
vaccin
efficaci
studi
base
weight
loss
histopatholog
analys
believ
age
mice
may
provid
addit
model
studi
agedepend
suscept
sarscov
howev
drawback
widespread
util
age
mous
model
difficulti
procur
larg
number
mice
month
age
although
strain
mice
target
delet
gene
evalu
follow
sarscov
infect
includ
beig
mice
glass
et
al
strain
notabl
clinic
cours
histopatholog
outcom
differ
wildtyp
strain
mice
mice
background
hogan
et
al
author
unpublish
data
mice
support
prolong
viral
replic
lung
accompani
patholog
viremia
dissemin
viru
liver
spleen
mice
suitabl
pathogenesi
studi
evalu
antivir
agent
wildtyp
strain
inbr
mice
suitabl
studi
immunopatholog
immunogen
efficaci
vaccin
candid
golden
syrian
hamster
strain
lvg
charl
river
laboratori
http
wwwcrivercomresearchmodelsandservicesresearchmodelslvghamstershtml
excel
model
sarscov
infect
viral
replic
accompani
patholog
chang
lung
includ
pneumon
consolid
robert
et
al
follow
intranas
inocul
tcid
sarscov
hamster
support
viral
replic
nasal
turbin
lung
peak
viral
replic
lung
occur
day
pi
clear
day
pi
viru
titer
nasal
turbin
fold
lower
lung
detect
day
pi
viremia
detect
day
pi
viru
recov
spleen
liver
histopatholog
chang
lung
accompani
sarscov
infect
hamster
day
pi
focal
area
interstiti
inflamm
consolid
visibl
day
pi
inflamm
pronounc
consolid
widespread
consolid
continu
day
pi
involv
surfac
area
lung
day
pi
patholog
chang
lung
resolv
robert
et
al
although
histopatholog
sign
diseas
pronounc
clinic
symptom
diseas
difficult
identifi
hamster
howev
use
exercis
wheel
evalu
overnight
activ
demonstr
hamster
infect
sarscov
less
activ
day
day
pi
prior
infect
compar
uninfect
mock
infect
anim
tabl
first
object
evid
clinic
ill
hamster
sever
strain
sarscov
evalu
hamster
model
includ
urbani
genbank
genbank
frankfurt
genbank
recombin
sarscov
infecti
clone
ic
express
spike
protein
genbank
deme
et
al
submit
primari
intranas
infect
tcid
hamster
sarscov
urbani
result
viru
titer
tcid
g
lung
day
pi
figur
c
wherea
primari
infect
result
significantli
lower
titer
tcid
g
day
pi
figur
find
suggest
compar
urbani
strain
slightli
attenu
hamster
model
reduct
peak
viru
titer
lung
follow
infect
sarscov
may
slightli
virul
strain
although
dosedepend
mortal
observ
hamster
die
follow
infect
sarscov
peak
viru
titer
lung
higher
peak
viru
titer
follow
infect
urbani
howev
differ
peak
viru
titer
achiev
statist
signific
figur
c
histopatholog
find
lung
follow
infect
sarscov
indistinguish
report
follow
infect
sarscov
urbani
figur
spike
protein
sarscov
urbani
isol
ident
amino
acid
sequenc
spike
protein
sequenc
differ
one
amino
acid
domain
antibodi
detect
hamster
sera
follow
primari
sarscov
infect
crossneutr
variou
viru
strain
homolog
virus
compar
degre
urbani
hamster
infect
strain
sarscov
protect
reinfect
homolog
viru
heterolog
virus
figur
although
hamster
inbr
speci
level
genet
variabl
among
golden
syrian
hamster
limit
close
outbr
coloni
sinc
furthermor
sinc
hamster
demonstr
high
level
viral
replic
pronounc
widespread
histopatholog
find
lung
clinic
evid
infect
tabl
suitabl
vaccin
efficaci
immunoprophylaxi
treatment
studi
although
avail
immunolog
reagent
hamster
limit
use
realtim
rtpcr
studi
cytokin
chemokin
respons
follow
infect
may
reveal
mechan
pathogenesi
model
lead
better
understand
pathogenesi
sar
human
ferret
mustela
furo
support
sarscov
replic
develop
multifoc
pulmonari
lesion
involv
surfac
area
lung
ter
meulen
et
al
ferret
infect
tcid
sustain
viru
replic
tcid
ml
day
pi
martina
et
al
ter
meulen
et
al
two
group
investig
util
ferret
model
somewhat
differ
find
martina
et
al
ter
meulen
et
al
weingartl
et
al
suggest
model
need
character
vaccin
efficaci
immunoprophylaxi
studi
clinic
symptom
follow
sarscov
infect
report
one
studi
martina
et
al
two
other
ter
meulen
et
al
weingartl
et
al
addit
studi
would
help
defin
biolog
variabl
outbr
speci
potenti
contribut
copathogen
variabl
observ
differ
studi
final
although
ferret
model
use
success
immunotherapi
prophylaxi
studi
ter
meulen
et
al
evalu
need
understand
poor
efficaci
immunogen
seen
mvavector
sarsvaccin
ferret
weingartl
et
al
compar
observ
anim
immun
similar
vaccin
bisht
et
al
chen
et
al
nhp
support
viral
replic
pneumon
variabl
clinic
symptom
patholog
depend
upon
speci
variou
strain
sarscov
includ
urbani
evalu
rhesu
macaqu
qin
et
al
row
et
al
cynomolgu
macaqu
lawler
et
al
mcauliff
et
al
qin
et
al
row
et
al
common
marmoset
greenough
et
al
african
green
monkey
squirrel
monkey
mustach
tamarin
squirrel
monkey
mustach
tamarin
suscept
sarscov
urbani
infect
author
unpublish
data
viru
detect
respiratori
tract
follow
inocul
monkey
develop
antibodi
sarscov
nhp
speci
studi
suscept
infect
variabl
degre
suscept
speci
singl
model
prefer
support
viral
replic
lung
tabl
viral
shed
respiratori
secret
develop
histopatholog
chang
consist
human
infect
includ
infect
type
type
ii
pneumocyt
diffus
alveolar
damag
vaccin
candid
evalu
nhp
vaccin
evalu
nhp
efficaci
reduc
titer
wildtyp
sarscov
challeng
viru
replic
andor
histopatholog
chang
immun
anim
compar
mockimmun
control
due
individu
variat
respons
outbr
anim
small
group
monkey
n
larg
enough
evalu
statist
outcom
studi
therefor
special
consider
given
conduct
vaccin
efficaci
studi
nhp
challeng
studi
conduct
larg
number
n
per
group
consider
also
given
histori
anim
use
util
highest
qualiti
monkey
avoid
freerang
period
life
known
infect
copathogen
avail
robert
et
al
vaccin
efficaci
studi
immunolog
respons
also
evalu
due
lack
avail
immunolog
reagent
includ
microarray
assay
rhesu
cynomolgu
macaqu
like
inform
nonhuman
primat
model
continu
sar
research
despit
limit
nhp
model
evalu
vaccin
candid
nhp
may
necessari
proceed
clinic
studi
cost
larg
studi
provid
need
sampl
size
special
consider
mention
limit
vaccin
efficaci
studi
promis
candid
although
addit
report
exist
anim
model
farm
mask
palm
civet
guinea
pig
vole
chepurnov
et
al
gao
et
al
wu
et
al
insuffici
data
avail
model
recommend
use
evalu
sarscov
vaccin
antivir
drug
use
model
evalu
would
necessit
thorough
character
model
includ
viral
replic
data
histopatholog
analysi
sarscov
mock
infect
anim
differ
speci
may
prove
use
studi
differ
aspect
sarscov
studi
pathogenesi
may
best
address
sever
speci
tool
avail
immunolog
analysi
wherea
vaccin
antivir
may
studi
model
allow
larg
enough
number
statist
evalu
best
anim
model
would
one
mimic
human
diseas
includ
featur
compar
level
mortal
seen
human
increas
suscept
older
anim
would
like
possibl
develop
model
increas
virul
sarscov
variou
speci
done
influenza
influenza
b
ebola
virus
effort
underway
mice
nhp
although
correl
protect
sar
associ
diseas
identifi
human
infect
neutral
antibodi
direct
sarscov
spike
protein
present
convalesc
human
serum
detect
experiment
infect
anim
martina
et
al
mcauliff
et
al
qin
et
al
robert
et
al
robert
et
al
row
et
al
subbarao
et
al
weingartl
et
al
wu
et
al
anim
studi
neutral
antibodi
provid
protect
reinfect
sarscov
prophylact
administ
monoclon
antibodi
specif
sar
spike
protein
passiv
transfer
sarscov
hyperimmun
sera
mice
greenough
et
al
subbarao
et
al
sui
et
al
traggiai
et
al
wang
et
al
hamster
robert
et
al
ferret
ter
meulen
et
al
prevent
reduc
sarscov
replic
associ
diseas
follow
challeng
monoclon
antibodi
specif
sar
spike
protein
administ
therapeut
ie
onset
infect
prevent
increas
viral
burden
reduc
associ
diseas
eg
consolid
hamster
robert
et
al
sera
mice
immun
recombin
spike
protein
inactiv
whole
sarscov
livevir
vector
vaccin
express
spike
protein
vsv
mva
dna
vaccin
express
sar
protein
shown
contain
neutral
antibodi
sarscov
tabl
tabl
passiv
transfer
immun
sera
mice
prevent
infect
sarscov
bisht
et
al
kapadia
et
al
stadler
et
al
yang
et
al
although
cell
mediat
immun
may
protect
role
viral
clearanc
resolut
diseas
human
popul
antibodi
alon
shown
prophylact
therapeut
benefit
data
sever
studi
strongli
suggest
effect
sarscov
vaccin
one
induc
high
sustain
level
neutral
antibodi
administr
neutral
mab
specif
sarscov
spike
protein
may
use
strategi
postexposur
treatment
prophylaxi
risk
popul
safeti
vaccin
alway
paramount
consider
must
alway
empir
determin
recombin
protein
vaccin
well
accept
among
safest
vaccin
although
alway
costeffect
recombin
protein
vaccin
excel
elicit
steril
immun
last
sever
year
depend
upon
immunogen
protein
vaccin
carri
risk
incomplet
inactiv
genet
recombin
circul
virus
revers
virul
phenotyp
recombin
protein
often
also
stabl
furthermor
adjuv
aluminum
salt
al
oh
al
alum
squalen
emuls
licens
use
us
europ
respect
may
ad
formul
proteinbas
vaccin
increas
immunogen
sarscov
spike
protein
identifi
major
target
neutral
antibodi
pang
et
al
sui
et
al
wang
et
al
yang
et
al
zhang
et
al
zhang
et
al
zhao
et
al
zhou
et
al
one
studi
demonstr
neutral
antibodi
specif
membran
protein
pang
et
al
role
antibodi
specif
sarss
protein
confer
protect
also
well
establish
greenough
et
al
robert
et
al
subbarao
et
al
sui
et
al
ter
meulen
et
al
traggiai
et
al
wang
et
al
vaccin
contain
recombin
sarsspik
protein
neutral
epitop
spike
protein
fairli
attract
fact
spike
protein
trimer
spike
protein
express
baculoviru
semlikivirusdefect
particl
express
system
respect
evalu
safeti
immunogen
efficaci
murin
hamster
model
bisht
et
al
kam
et
al
press
protein
demonstr
excel
immunogen
tabl
tabl
efficaci
protect
challeng
anim
model
inactiv
wholeviru
vaccin
also
shown
immunogen
efficaci
tabl
tabl
like
recombin
protein
vaccin
vaccin
contain
substanti
amount
spike
protein
elicit
neutral
antibodi
level
similar
elicit
recombin
protein
vaccin
tabl
confer
protect
subsequ
challeng
vaccin
anim
like
recombin
protein
vaccin
inactiv
wholeviru
vaccin
would
like
rel
stabl
formul
potenti
benefit
inactiv
wholeviru
vaccin
recombin
protein
vaccin
conform
spike
protein
may
maintain
antibodi
viral
protein
may
contribut
protect
immun
major
disadvantag
inactiv
wholeviru
vaccin
would
need
work
whole
infecti
viru
prepar
vaccin
potenti
incomplet
inactiv
process
manufactur
vaccin
although
vaccin
elicit
humor
cellular
immun
may
provid
theoret
advantag
vaccin
produc
neutral
antibodi
respons
may
suffici
protect
sarscov
infect
convalesc
human
sera
mean
plaqu
reduct
neutral
titer
normal
distribut
titer
around
mean
titer
neutral
antibodi
necessari
achiev
protect
human
popul
expos
sarscov
known
recombin
dna
livevector
vaccin
combin
advantag
laboratori
worker
expos
live
sarscov
vaccin
product
although
dna
vector
potenti
safe
stabl
rel
inexpens
vaccin
proven
highli
efficaci
immunogen
human
dna
vaccin
express
sarss
protein
evalu
mice
stimul
humor
cellmedi
immun
wang
et
al
yang
et
al
efficaci
antibodi
gene
respons
protect
sarscov
dna
vaccin
demonstr
greater
potenti
primeboost
regimen
speci
robust
immun
induc
dna
vector
alon
tabl
howev
combin
may
lessen
econom
benefit
dnavector
approach
necessit
licensur
one
vaccin
human
use
sever
live
virus
test
vector
express
sarscov
protein
includ
mva
vsv
adenoviru
tabl
vector
equal
immunogen
efficaci
data
avail
studi
nevertheless
vector
elicit
neutral
antibodi
protect
immun
express
spike
protein
sarscov
vector
express
sarscov
protein
includ
n
confer
protect
challeng
sarscov
addit
n
gene
enhanc
immunogen
efficaci
vaccin
encod
spike
protein
alon
summari
vector
vaccin
test
immunogen
protect
efficaci
anim
model
test
list
tabl
livevector
vaccin
test
date
one
construct
mva
variabl
immunogen
variabl
efficaci
ferret
vaccin
vector
confer
protect
may
led
format
hepat
lesion
follow
challeng
sarscov
find
contrast
data
report
use
mva
vector
vaccin
mice
rhesu
macaqu
significantli
immunogen
efficaci
possibl
immunogen
mvavector
vaccin
like
dna
vaccin
vari
differ
speci
final
combin
vaccin
may
prove
immunogen
dna
vaccin
inactiv
vaccin
vector
vaccin
alon
thorough
studi
combin
dna
peptid
vaccin
demonstr
regimen
greatli
enhanc
neutral
antibodi
respons
sarss
protein
woo
et
al
howev
complex
develop
two
system
requir
primeboost
regimen
disadvantag
comparison
singl
immun
highli
immunogen
vaccin
one
may
question
whether
complex
regimen
warrant
singl
vaccin
administ
produc
steril
immun
enhanc
diseas
mortal
observ
kitten
immun
felin
infecti
periton
viru
fipv
typei
coronaviru
subsequ
expos
fipv
vennema
et
al
weiss
scott
enhanc
diseas
associ
fipv
well
understood
appar
mediat
subneutr
antibodi
facilit
viral
entri
macrophag
via
fcreceptormedi
mechan
corapi
et
al
corapi
et
al
hohdatsu
et
al
hohdatsu
et
al
olsen
et
al
olsen
et
al
absenc
serotypespecif
protect
antibodi
presenc
low
level
subneutr
level
viru
specif
antibodi
human
virus
includ
respiratori
syncyti
viru
rsv
dengu
viru
demonstr
enhanc
diseas
upon
reinfect
connor
et
al
connor
et
al
halstead
kakuk
et
al
murphi
et
al
sullivan
diseas
enhanc
case
rsv
occur
absenc
protect
titer
antibodi
like
mediat
cellular
immun
respons
lead
immunopatholog
antibodi
depend
entri
observ
dengu
viru
infect
similar
occur
fipv
infect
dengu
viru
infect
antibodi
enhanc
entri
occur
previous
infect
individu
reinfect
second
serotyp
dengu
viru
antibodi
first
serotyp
dengu
viru
protect
second
serotyp
viru
entri
suscept
cell
facilit
fcreceptormedi
mechan
nonprotect
antibodi
although
sarscov
antigen
nucleic
acid
detect
pulmonari
macrophag
lung
infect
human
experiment
infect
anim
unclear
whether
due
phagocytosi
virion
antibodi
receptor
mediat
viral
entri
li
et
al
yilla
et
al
macrophag
infect
ex
vivo
support
replic
sarscov
typeii
coronaviru
howev
discuss
vitro
data
suggest
enhanc
entri
sarscov
suscept
cell
may
occur
presenc
nonneutr
subneutr
level
antibodi
pseudotyp
lentivirus
express
spike
protein
sarscov
isol
civet
cat
demonstr
enhanc
entri
human
renal
adenocarcinoma
cell
line
incub
antibodi
human
sarscov
isol
yang
et
al
enhanc
observ
pseudotyp
virus
express
spike
protein
human
sarscov
isol
enhanc
demonstr
level
viru
entri
viru
replic
yet
determin
enhanc
replic
occur
presenc
subneutr
level
antibodi
furthermor
vitro
find
link
known
compon
human
diseas
infect
vivo
anim
model
phenomenon
report
pseudotyp
virus
observ
human
isol
sarscov
observ
cell
reproduc
accord
et
al
et
al
vitro
experi
examin
product
enhanc
sarscov
replic
differenti
human
macrophag
presenc
absenc
sarsspecif
antibodi
demonstr
sarscov
abl
enter
cell
entri
enhanc
antibodi
sarscov
viabl
viru
recov
macrophag
cultur
two
day
viral
entri
qrtpcr
analysi
show
littl
viral
replic
cell
ter
meulen
et
al
ex
vivo
experi
examin
sarscov
urbani
mouseadapt
strain
replic
primari
murin
balbc
strain
macrophag
isol
lung
spleen
peritoneum
fail
demonstr
product
infect
well
robert
cheng
subbarao
unpublish
data
sever
experi
evalu
sarscov
infect
variou
anim
model
presenc
neutral
subneutr
level
sarsantisera
mab
specif
sarscov
protein
evid
diseas
enhanc
seen
studi
appreci
level
neutral
antibodi
achiev
follow
vaccin
see
refer
tabl
furthermor
enhanc
diseas
report
respiratori
tissu
gi
tissu
primari
site
viral
replic
sarscov
infect
singl
set
experi
weingartl
et
al
ferret
immun
mvasarss
via
interperiton
subcutan
rout
pfu
vaccin
per
ferret
day
boost
regimen
day
challeng
intranas
pfuferret
sarscov
day
mvasarss
vaccin
ferret
demonstr
low
level
neutral
antibodi
sarscov
one
week
booster
immun
ie
day
titer
less
strang
neutral
antibodi
group
detect
day
prior
challeng
signific
differ
observ
level
viru
detect
pharyng
swab
anim
vaccin
mvasarss
control
anim
follow
challeng
sarscov
foci
hepat
necrosi
observ
mvasarssvaccin
anim
lesser
extent
anim
immun
mva
vector
alon
pb
unclear
mvasarss
vaccin
poorli
immunogen
indic
low
level
transient
detect
neutral
antibodi
ferret
sinc
similar
vaccin
immunogen
efficaci
mice
nhp
also
unclear
memori
antibodi
respons
observ
mvasarss
immun
anim
unabl
neutral
viru
clear
viru
ferret
faster
viru
clear
mockimmun
ferret
possibl
copathogen
caus
hepat
examin
possibl
copathogen
might
play
role
observ
report
ferret
also
possibl
observ
phenomenon
may
limit
specif
vector
mva
anim
model
ferret
final
although
elev
level
liver
enzym
follow
sarscov
infect
report
human
case
sar
hepat
rare
ever
report
sar
patient
yang
et
al
therefor
difficult
interpret
find
hepat
ferret
determin
find
relev
possibl
diseas
enhanc
sarsvaccin
anim
although
unconfirm
may
possibl
hepat
lesion
observ
studi
occur
cellmedi
mechan
similar
observ
lung
rsv
infect
follow
use
formalin
inactiv
vaccin
find
hepat
follow
use
mvavector
vaccin
ferret
merit
evalu
although
correl
immun
known
human
case
sar
current
sar
anim
model
much
known
gener
protect
sarscov
infect
vaccin
monoclon
antibodi
specif
sarscov
spike
protein
highli
efficaci
prophylaxi
although
concern
regard
potenti
enhanc
diseas
previous
vaccin
anim
address
experiment
bodi
literatur
support
complet
partial
protect
sever
anim
model
follow
varieti
vaccin
strategi
suggest
success
sar
vaccin
made
golden
syrian
hamster
day
old
intranas
inocul
one
four
sarscov
strain
n
b
urbani
n
c
n
n
sarscov
tcid
hamster
evalu
viral
replic
follow
primari
infect
four
hamster
per
strain
hamster
sacrif
day
postinfect
evalu
protect
secondari
infect
remain
hamster
challeng
day
infect
indic
homolog
heterolog
strain
sarscov
per
group
n
tcid
hamster
sacrif
day
later
bar
indic
mean
titer
viru
detect
wv
lung
homogen
tcid
assay
vero
cell
day
initi
infect
day
challeng
error
bar
indic
standard
error
dash
line
indic
limit
detect
tcid
g
lung
lung
sarscov
infect
urbani
b
c
e
hamster
day
pi
show
confluent
pneumon
consolid
hematoxylinandeosin
stain
c
e
sarscov
antigen
ihc
assay
antigen
red
b
f
consolid
area
asterisk
bronchial
epithelium
arrow
origin
magnif
c
e
b
f
neutral
titer
achiev
follow
vaccin
recombin
protein
vaccin
bisht
et
al
vaccin
administ
reciproc
neutral
titer
log
sarscov
strain
use
immunogen
design
parenthes
strain
design
urbani
strain
urbani
fra
utah
b
sigmaaldrich
mg
monophosphoryl
lipid
detoxifi
endotoxin
minnesota
mpl
mg
synthet
trehalos
dicorynomycol
tdm
oil
